Again, low expression of SLC16A2 was associated with improved patient survival in HPV+ HNSCC patients (p = 0.0036, FDR = 0.047) (Figure 4H), but not in patients with HPV- HNSCC (p = 0.26, FDR = 0.48) (Figure 4I). Here, SLC16A2 is linked to head and neck squamous cell carcinoma.